A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. Sun Li et al. JAMA oncology 2019 Oct

Main|Search|PHGKB




Last Posted: Oct 10, 2019

---

• A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
  Sun Li et al. JAMA oncology 2019 Oct
• BRCA testing in unaffected young women in the United States, 2006-2017.
  Guo Fangjian et al. Cancer 2019 Sep
• Genetic testing in ovarian cancer - clinical impact and current practices.
  Knabben Laura et al. Hormone molecular biology and clinical investigation 2019 Oct
• No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.
  Salvador Shannon et al. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2017 Jun 39(6) 480-493
• After a Breast Cancer Diagnosis, Men May Be More Likely to Die than Women
  NCI, October 2, 2019
• Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
  NJ Curtin et al, Nature Rev Clin Oncology, October 3, 2019
• BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
  Oh Mok et al. Journal of the National Cancer Institute 2018 110(11) 1178-1189
• Mathew Knowles reveals he is battling breast cancer: 'We need men to speak out'
  H FitzPatrick et al, ABC Good Morning America, October 2, 2019
• [Views of Icelandic women towards genetic counseling - and testing of BRCA2 mutations].
  Jonsdottir Thordis et al. Laeknabladid 104(6) 289-296
• Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
  Johns Dana et al. Journal of women's health (2002) 2017 26(6) 702-706

more